ClinicalTrials.gg
CompletedNCT04784442Updated May 10, 2024Results posted

A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

A Phase 2 interventional study of 180mg of ETC-1002(bempedoic acid) and 120mg of ETC-1002(bempedoic acid) in Hypercholesterolemia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
8th of 21
188 · median 126
Started
2021
the only one that year
Phase 2
10 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
1 of 21
Otsuka Pharmaceutical Co., Ltd.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 10 in phase 2, and was the 15th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have obtained to all of the observation/examination/evaluation items specified in the protocol
  • Patients must be on stable statin therapy defined as atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin, or fluvastatin daily[and other lipid-modifying therapies(LMTs) if needed] at least 4 weeks(6 weeks for fibrates) prior to screening and above LDL-C control target. Or Patients for statin intolerant must be on stable LMT(s) at least 4 weeks prior to screening and above LDL-C control target. Statin intolerance defined as an inability to tolerate 1 or more statins due to an adverse safety effect that started or increased during statin therapy and resolved or improved when statin therapy was discontinued or decreased. Patients on the lowest or under the dosage of the approved dose of statin or unable to tolerate any statin at any dose were eligible. Patients could continue taking the lowest or under the dosage of the approved dose of statin therapy or taking other LMTs throughout the study provided that it was stable and well tolerated.
  • Fasting mean TG level \< 400 mg/dL from measurements at screening
  • Other protocol specific inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding or who have a positive pregnancy test (urine) result at screening or baseline visits
  • Sexually active male subjects or sexually active female subjects of who do not agree to practice 2 different methods of or to remain abstinent during the trial and for 30 days after final IMP administration test (urine) result at screening or baseline visits
  • Patients with homozygous familial hypercholesterolemia (HoFH)
  • Patients with a history or current symptoms of any of the following cardiovascular diseases within 3 months prior to screening or before baseline visit

    • Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, stroke, , symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, or decompensated heart failure
    • Abdominal aortic aneurysm
    • Unexplained syncope or long- syndrome, family history of long-QT syndrome, or risk factors for Torsade de Pointes, such as persistent hypokalemia or second- or third-degree atrioventricular block (except when controlled by medication, etc)
  • Uncontrolled hypertension, defined as follows:

    • Sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening
  • Patients with uncontrolled and serious hematologic or coagulation disorders or with of \<10.0 g/dL at screening
  • Patients with type 1 diabetes or uncontrolled type 2 diabetes with (HbA1c) of ≥9% at screening
  • Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × at screening
  • Patients with liver disease or dysfunction, including:

    • Positive serology for surface antigen (HBsAg) and/or antibodies at screening
    • (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN and/or total of ≥2 × ULN
  • Patients with creatine kinase (CK) elevation( >3 × ULN) at screening
  • Patients with renal dysfunction or nephritic syndrome or a history of nephritis and with estimated (eGFR) of ≤30 mL/min/1.73m2 at screening
  • Other protocol specific inclusion criteria may apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    ETC-1002 180mg

    Drug: 180mg of ETC-1002(bempedoic acid)

  • Experimental
    ETC-1002 120mg

    Drug: 120mg of ETC-1002(bempedoic acid)

  • Experimental
    ETC-1002 60mg

    Drug: 60mg of ETC-1002(bempedoic acid)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change in LDL-C From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1. When LDL-C at Week 12 was missing, the missing value was imputed using the last observation carried forward from the start of the IMP administration to 2 days after the final IMP administration.

    Time frame: Baseline, week12

Secondary outcomes

  1. Percent Change in HDL Cholesterol From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  2. Percent Change in Non-HDL Cholesterol From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  3. Percent Change in Total Cholesterol From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  4. Percent Change in Triglycerides From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  5. Percent Change in Apolipoprotein B From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  6. Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  7. Percent Change in Hemoglobin A1c From Baseline to Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

    Time frame: Baseline, week12

  8. Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12

    The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.

    Time frame: Baseline, week12

  9. Proportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 12

    The proportion of subjects whose LDL-C value achieves \<70 mg/dL at Week 12.

    Time frame: Baseline, week12

07

Results

Posted Mar 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Started47464847
Completed44464646
Not completed3021
Withdrew: Adverse event1021
Withdrew: Protocol violation1000
Withdrew: Non-compliance with study drug1000

Outcome measures

PrimaryPercent Change in LDL-C From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1. When LDL-C at Week 12 was missing, the missing value was imputed using the last observation carried forward from the start of the IMP administration to 2 days after the final IMP administration.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in LDL-C From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in LDL-C From Baseline to Week 12-10.59 ± 2.153-21.85 ± 2.156-21.26 ± 2.095-1.92 ± 2.117
Statistical analysis
  • ETC-1002 180 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -19.35 · 95% CI -24.81 to -13.88The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
  • ETC-1002 120 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -19.93 · 95% CI -25.45 to -14.41The least squares mean difference was calculated as the value for the ETC-1002 120 mg arm minus the value for the placebo arm.
  • ETC-1002 60 mg vs Placebo · ANCOVA · p = 0.002 · Least squares mean difference: -8.67 · 95% CI -14.22 to -3.12
SecondaryPercent Change in HDL Cholesterol From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in HDL Cholesterol From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in HDL Cholesterol From Baseline to Week 120.16 ± 2.208-0.65 ± 2.190-7.29 ± 2.1393.08 ± 2.155
SecondaryPercent Change in Non-HDL Cholesterol From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Non-HDL Cholesterol From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in Non-HDL Cholesterol From Baseline to Week 12-8.86 ± 2.019-18.29 ± 2.021-16.01 ± 1.956-1.62 ± 1.988
SecondaryPercent Change in Total Cholesterol From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Total Cholesterol From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in Total Cholesterol From Baseline to Week 12-6.42 ± 1.665-13.61 ± 1.650-13.56 ± 1.599-0.55 ± 1.621
SecondaryPercent Change in Triglycerides From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Triglycerides From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in Triglycerides From Baseline to Week 12-9.09 ± 6.286-5.62 ± 6.2909.17 ± 6.151-0.08 ± 6.219
SecondaryPercent Change in Apolipoprotein B From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Apolipoprotein B From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in Apolipoprotein B From Baseline to Week 12-8.18 ± 1.715-14.59 ± 1.709-12.47 ± 1.704-2.13 ± 1.704
SecondaryPercent Change in High Sensitivity C Reactive Protein From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12150.54 ± 62.4941.02 ± 62.418-34.58 ± 62.7450.98 ± 61.513
SecondaryPercent Change in Hemoglobin A1c From Baseline to Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.

Time frame:
Baseline, week12
Reported as:
Least squares mean · Percent Change
Percent Change in Hemoglobin A1c From Baseline to Week 12
Percent ChangeETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Percent Change in Hemoglobin A1c From Baseline to Week 120.11 ± 0.591-0.40 ± 0.596-0.21 ± 0.592-0.05 ± 0.578
SecondaryProportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12

The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.

Time frame:
Baseline, week12
Reported as:
Number · participants
Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12
participantsETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 121526281
SecondaryProportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 12

The proportion of subjects whose LDL-C value achieves \<70 mg/dL at Week 12.

Time frame:
Baseline, week12
Reported as:
Count of participants · Participants
Proportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 12
ParticipantsETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Proportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 120100

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 28 (+7) days after the last dose of study medication.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETC-1002 60 mg0/47 (0%)0/47 (0%)23/47 (48.9%)
ETC-1002 120 mg0/46 (0%)0/46 (0%)17/46 (37%)
ETC-1002 180 mg0/47 (0%)1/47 (2.1%)21/48 (43.8%)
Placebo0/48 (0%)1/48 (2.1%)9/47 (19.1%)
Most frequent serious events
Most frequent serious events
EventETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
Calculus urinaryRenal and urinary disorders0/470/461/470/48
Dental cystGastrointestinal disorders0/470/460/471/48
Most frequent other events
Showing 10 of 25
Most frequent other events
EventETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlacebo
HeadacheNervous system disorders0/475/462/480/47
PyrexiaGeneral disorders5/474/461/482/47
Hepatic function abnormalHepatobiliary disorders2/470/465/480/47
Abdominal pain upperGastrointestinal disorders4/471/460/480/47
MalaiseGeneral disorders1/473/463/480/47
Vaccination site painGeneral disorders1/473/460/481/47
Blood uric acid increasedInvestigations2/473/461/480/47
DiarrhoeaGastrointestinal disorders3/471/461/481/47
ArthralgiaMusculoskeletal and connective tissue disorders3/472/462/480/47
MyalgiaMusculoskeletal and connective tissue disorders1/471/463/483/47

Baseline characteristics

For the full analysis set (FAS), a total of 186 subjects (45 for the 60 mg group, 46 for the 120 mg group, and 48 for the 180 mg group were included in the ETC-1002 group, and 47 subjects were included in the placebo group).

Age, Categorical
Age, Categorical(Participants)ETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlaceboTotal
<=18 years00000
Between 18 and 65 years2827232098
>=65 years1719252788
Age, Continuous
Age, Continuous(years)ETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlaceboTotal
Mean60.9 ± 9.2660.4 ± 8.9460.4 ± 11.9863.0 ± 10.6561.2 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)ETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlaceboTotal
Female1616161260
Male29303235126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlaceboTotal
Asian45464847186
Region of Enrollment
Region of Enrollment(participants)ETC-1002 60 mgETC-1002 120 mgETC-1002 180 mgPlaceboTotal
Japan45464847186
08

Study locations

1 site
  • Tokyo-Eki Center-Building Clinic
    Chuo-ku,Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — : Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2022, 12 months.

Results were first posted in Mar 2024, 1 year 10 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 12 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2021
First posted
Mar 5, 2021
StartActual
Mar 24, 2021
Primary completionActual
Apr 18, 2022
CompletionActual
May 17, 2022
Results first posted
Mar 4, 2024
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04784442
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Mar 24, 2021
Primary completion
Apr 18, 2022
Completion
May 17, 2022
Results posted
Mar 4, 2024
Last update
May 10, 2024

Study contacts

Takehisa Matsumaru
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion